Can I read PSMA-PET/CT-Guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): Findings of Detection Rate, Effect on Cancer Management, and Early Toxicity From a Phase 2 Randomized Controlled Trial on EtoBox?

PSMA-PET/CT-Guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): Findings of Detection Rate, Effect on Cancer Management, and Early Toxicity From a Phase 2 Randomized Controlled Trial by Claire Petit; Guila Delouya; Daniel Taussky; Maroie Barkati; Carole Lambert; Marie-Claude Beauchemin; Sebastien Clavel; Gary Mok; Anne-Sophie Gauthier Paré; Thu-van Nguyen; Danny Duplan; Khun Visith Keu; Fred Saad; Daniel Juneau; Cynthia Ménard is a Medicine article available to read on EtoBox.

What is PSMA-PET/CT-Guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): Findings of Detection Rate, Effect on Cancer Management, and Early Toxicity From a Phase 2 Randomized Controlled Trial about?

Purpose Prostate-specific membrane antigen (PSMA) ligand positron emission tomography (PET) is increasingly integrated in prostate cancer management because of its diagnostic performance. We sought to evaluate the effect of PSMA-PET/computed tomography (CT)–guided intensification of radiation therapy (PSMAgRT) on patient outcomes. Here, we report secondary trial endpoints including the rate of new lesion detection, effect on prostate cancer management, and treatment-related toxicities. Methods and Materials In this phase 2 cohort multiple randomized controlled trial across 2 institutions, men with prostate cancer planned for RT were randomly selected for PSMAgRT across 4 strata: oligometastatic, high risk (Cancer of the Prostate Risk Assessment ≥6 or cN1), salvage post-RT, and salvage postprostatectomy (RP). Primary endpoint was failure-free survival at 5 years, with analysis pending further follow-up. Secondary endpoints included new lesion detection yield of PSMA-PET/CT, acute and delayed toxicities, effect on prostate cancer management, and health-related quality-of-life outcomes. This trial is registered with ClinicalTrials.gov, identifier NCT03525288, companion to registry NCT

Who reads PSMA-PET/CT-Guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): Findings of Detection Rate, Effect on Cancer Management, and Early Toxicity From a Phase 2 Randomized Controlled Trial?

Author

Claire Petit; Guila Delouya; Daniel Taussky; Maroie Barkati; Carole Lambert; Marie-Claude Beauchemin; Sebastien Clavel; Gary Mok; Anne-Sophie Gauthier Paré; Thu-van Nguyen; Danny Duplan; Khun Visith Keu; Fred Saad; Daniel Juneau; Cynthia Ménard

Publisher

Elsevier BV

Published

2023

Language

EN

Field

Medicine (Health Sciences)